These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 22711060)

  • 1. Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Qi WX; Tang LN; He AN; Shen Z; Lin F; Yao Y
    Lung; 2012 Oct; 190(5):477-85. PubMed ID: 22711060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy for advanced non-small cell lung cancer in the elderly population.
    Santos FN; de Castria TB; Cruz MR; Riera R
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010463. PubMed ID: 26482542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy for advanced non-small cell lung cancer in the elderly population.
    Santos FN; Castria TB; Cruz MR; Riera R
    Sao Paulo Med J; 2016; 134(5):465-466. PubMed ID: 27901246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis comparing doublet and single cytotoxic agent therapy as first-line treatment in elderly patients with advanced nonsmall-cell lung cancer.
    Wang S; Wang Q; Tian J; Zhou Z; Jiao L; Fu Y; Chen S; Zhang J; Xu L
    J Int Med Res; 2015 Dec; 43(6):727-37. PubMed ID: 26438014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials.
    Yu Y; Xu X; Du Z; Shi M
    Cancer Chemother Pharmacol; 2012 May; 69(5):1265-75. PubMed ID: 22297708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC).
    Yang J; He J; Yu M; Li T; Luo L; Liu P
    Medicine (Baltimore); 2016 Dec; 95(50):e5599. PubMed ID: 27977596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
    Qi WX; Tang LN; He AN; Shen Z; Yao Y
    Breast; 2013 Jun; 22(3):314-9. PubMed ID: 22901442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis.
    Des Guetz G; Uzzan B; Nicolas P; Valeyre D; Sebbane G; Morere JF
    Crit Rev Oncol Hematol; 2012 Dec; 84(3):340-9. PubMed ID: 22534083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status.
    Gijtenbeek RG; de Jong K; Venmans BJ; van Vollenhoven FH; Ten Brinke A; Van der Wekken AJ; van Geffen WH
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD013382. PubMed ID: 37419867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
    Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
    Qi WX; Shen Z; Yao Y
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):99-106. PubMed ID: 21607554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doublets versus single-agent therapy as first-line therapy for elderly patients with advanced non-small cell lung cancer? A systematic review of randomised controlled trials.
    Xu CA; Chang ZY; Wang XJ; Qi HY
    Int J Clin Pract; 2013 Nov; 67(11):1118-27. PubMed ID: 24165426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing single-agent with doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2: a meta-analysis.
    Luo L; Hu Q; Jiang JX; Yang X; Dinglin XX; Lin X; Yao HR
    Asia Pac J Clin Oncol; 2015 Sep; 11(3):253-61. PubMed ID: 25866140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
    de Castria TB; da Silva EM; Gois AF; Riera R
    Cochrane Database Syst Rev; 2013 Aug; (8):CD009256. PubMed ID: 23949842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.
    Zhang XW; Ma YX; Sun Y; Cao YB; Li Q; Xu CA
    Target Oncol; 2017 Jun; 12(3):309-321. PubMed ID: 28353074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
    Pan G; Ke S; Zhao J
    Target Oncol; 2013 Jun; 8(2):107-16. PubMed ID: 23516098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis.
    Russo A; Rizzo S; Fulfaro F; Adamo V; Santini D; Vincenzi B; Gebbia N; Carreca I
    Cancer; 2009 May; 115(9):1924-31. PubMed ID: 19235250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials.
    Rajeswaran A; Trojan A; Burnand B; Giannelli M
    Lung Cancer; 2008 Jan; 59(1):1-11. PubMed ID: 17720276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis of platinum plus gemcitabine or vinorelbine in the treatment of advanced non-small-cell lung cancer.
    Gao G; Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
    Lung Cancer; 2009 Sep; 65(3):339-44. PubMed ID: 19144444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
    J Cancer Res Clin Oncol; 2013 Jan; 139(1):25-38. PubMed ID: 22864816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.